Celldex Therapeutics, Inc. (CLDX)
| Market Cap | 2.61B |
| Revenue (ttm) | 1.55M |
| Net Income (ttm) | -258.76M |
| Shares Out | 78.46M |
| EPS (ttm) | -3.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 622,489 |
| Open | 33.96 |
| Previous Close | 33.66 |
| Day's Range | 33.19 - 34.61 |
| 52-Week Range | 17.85 - 35.79 |
| Beta | 1.20 |
| Analysts | Strong Buy |
| Price Target | 46.60 (+40.21%) |
| Earnings Date | May 4, 2026 |
About CLDX
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. The company’s drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. It develops clinical programs, including Barzolvolimab (CDX-0159), a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity for treating chronic urticarias,... [Read more]
Financial Performance
In 2025, Celldex Therapeutics's revenue was $1.55 million, a decrease of -77.99% compared to the previous year's $7.02 million. Losses were -$258.76 million, 63.9% more than in 2024.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CLDX stock is "Strong Buy." The 12-month stock price target is $46.6, which is an increase of 40.21% from the latest price.
News
Celldex Therapeutics Transcript: H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference
Barzolvolimab demonstrates rapid, durable, and high complete response rates in urticaria, with phase III data expected in Q4. Positioned for both first- and second-line advanced therapy markets, the company is well-funded and advancing a promising pipeline, including CDX-622.
Celldex to Present at Upcoming Investor Conference
HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright's 4th Annual Inflammatory Skin Disease Vi...
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the closing of its previously announced underwritten public off...
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 sh...
Celldex Announces Proposed Public Offering of Common Stock
HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the s...
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026
- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life - - Data further d emonstrates first-in-class and best-in-disease barzolvolimab profile -
Celldex Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Phase III CSU and CIndU studies showed unprecedented efficacy and rapid enrollment, with barzolvolimab positioned for both frontline and advanced therapy in severe urticaria. Key data readouts are expected for PN in summer, CSU in Q4, and atopic dermatitis by year-end.
Celldex Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
Multiple late-stage trials are progressing rapidly, with key data readouts for prurigo nodularis, CSU, and atopic dermatitis expected this year. Barzolvolimab is positioned for both frontline and second-line use, with a focus on rapid, durable efficacy and convenient subcutaneous administration.
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026
- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks - - Greatly improved qu...
Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2025 and provided a corporate update.
Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria
HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company's global Phase 3 program of barzolvolimab in chronic spontaneous urti...
Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab's First-in-Class and Best-in-Disease Profile
HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company's Phase 2 clinical trials of barzolvolimab in chronic spontaneous ur...
Celldex Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Multiple phase 3 studies are progressing in urticaria and dermatitis, with key data readouts expected in 2026. Durable efficacy and a strong safety profile are generating physician enthusiasm, while a robust cash position supports ongoing development and pipeline expansion.
Celldex to Present at Upcoming Investor Conferences
HAMPTON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences:
Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism
HAMPTON, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the initiation of its global Phase 3 trial (EMBARQ-ColdU and SD) designed to establish the efficacy and safety of...
Celldex Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Late-stage clinical programs are advancing, with key phase III and II data expected in 2026. Barzol is positioned for broad use and premium pricing, while CDX-622's MAD data is due Q3 2026. Indication expansion and partnerships are under active consideration.
Celldex Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit
Durable 41% complete response in CSU was observed seven months post-treatment, surpassing competitors. Phase III studies in CSU are progressing, with key data and additional phase II readouts in PN, AD, and CDX-622 expected through 2026.
Celldex Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Recent data highlight strong efficacy and safety for barzolvolimab in urticaria, with phase III studies progressing and additional indications under development. The bispecific CDX-622 program shows promising early results, and a robust cash position supports advancement through 2027.
Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer
HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished...
Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025
Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU
Celldex Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Barzolvolimab is advancing through global Phase III trials for CSU and other urticaria subtypes, showing unprecedented durability and a favorable safety profile. The pipeline includes a bispecific antibody, CDX-622, targeting additional inflammatory diseases. Cash reserves support operations through 2027, with key data readouts expected in 2024 and 2026.
Celldex to Present at Morgan Stanley 23rd Annual Global Healthcare Conference
HAMPTON, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced that management will participate in a fireside chat today, September 9th, 2025, at the Morgan Stanl...
Celldex Therapeutics Pulls Plug On Eosinophilic Esophagitis Investigational Drug As Data Falls Short
On Tuesday, Celldex Therapeutics, Inc. CLDX released topline results from its ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE), a chronic inflammatory disease of the esophagus.
Celldex Therapeutics Transcript: Study Update
Barzolvolimab achieved significant mucosal mast cell depletion in EoE but did not improve symptoms or endoscopic outcomes, indicating mast cells are not a primary driver in this disease. The safety profile remained favorable, and future development will focus on other indications.
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis (EoE)
HAMPTON, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported topline results from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esoph...